ZM 323881 HCl is primarily used in biochemical and pharmacological research as a selective inhibitor of VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2). Its application is significant in studying angiogenesis, the process by which new blood vessels form from pre-existing vessels. Researchers utilize this compound to inhibit VEGFR-2 signaling pathways, which are crucial for vascular development and tumor growth. By blocking these pathways, ZM 323881 HCl helps in understanding the mechanisms of cancer progression and the potential for therapeutic interventions targeting angiogenesis. Additionally, it is employed in preclinical studies to evaluate the efficacy of anti-angiogenic drugs in various cancer models, providing insights into the development of novel cancer treatments.